In the field of target therapy for lung cancer, epidermal growth factor receptor (EGFR) T790M mutation gradually emerges with the initial mutation of 19del or L858R unchanged, thus leading to AR to the first- or second-generation tyrosine kinase inhibitors (TKIs) (44, 45). This evidence concerns the gene EGFR and lung cancer.